ATH434

ATH434 has been studied in 2 papers since 2021: none in people yet, 2 in animals. The research so far is in animals. The newest paper, Sep 29, 2022: “ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism”.

InterventionPhase 2

2 papers study it7 findingsUpdated

See all 2 papers on ATH434

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 4 trials, none about aging, 2 with no results posted.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • 4 trials, none about aging, 2 with no results posted
  • Funders: University of Melbourne and 4 more
  • 3 of 4 trials sponsored by its developers
  • Animals2

What did studies of ATH434 find?

7

Studies of ATH434 measured 7 outcomes, among them substantia nigra neurodegeneration, motor impairment and bulbar iron and copper.

Substantia nigra neurodegeneration

downin mice1

1 study
  1. ATH434 decreases substantia nigra neurodegeneration in mice (tau knockout mice).

    “which coincided with a reduction in iron levels and reduced neurodegeneration in the substantia nigra.”

    Animalstau knockout micesubstantia nigra30 mg/kg/day6 weeks

    ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Motor impairment

downin mice1

1 study
  1. ATH434 prevents motor impairment in mice (tau knockout mice).

    “ATH434 was able to prevent the development of motor impairment in aged tau-/- mice”

    Animalstau knockout mice30 mg/kg/day6 weeks

    ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Bulbar iron and copper

downin mice1

1 study
  1. ATH434 decreases bulbar iron and copper in mice (tau knockout mice).

    “which coincided with a reduction in bulbar iron and copper levels”

    Animalstau knockout miceolfactory bulb30 mg/kg/day6 weeks

    ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

More on Bulbar iron and copper

Hyposmia

downin mice1

1 study
  1. ATH434 prevents hyposmia in mice (tau knockout mice).

    “ATH434 was able to prevent the development of hyposmia in young tau-/- mice”

    Animalstau knockout mice30 mg/kg/day6 weeks

    ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

More on Hyposmia

Proportion of neurons with nuclear Hu+ translocation

downin mice1

1 study
  1. ATH434 decreases proportion of neurons with nuclear Hu+ translocation in mice (A53T alpha-synuclein transgenic mice; treatment and prevention groups).

    “was reduced in both groups when ATH434 was administered.”

    AnimalsA53T alpha-synuclein transgenic mice; treatment and prevention groupsenteric nervous system30 mg/kg/day3 or 4 months

    ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease

    Journal of Parkinson's disease

More on Proportion of neurons with nuclear Hu+ translocation

Gut transit time

no changein mice1

1 study
  1. ATH434 showed no clear effect on gut transit time in mice.

    “did not alter deficits in gut transit time when compared to vehicle-treated A53T mice.”

    AnimalsA53T alpha-synuclein transgenic mice treated before slowed propulsion; compared with vehicle-treated A53T micegut30 mg/kg/day3 months

    ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease

    Journal of Parkinson's disease

Colonic propulsion

upin mice1

1 study
  1. ATH434 improves colonic propulsion in mice (A53T alpha-synuclein transgenic mice with established dysfunction) (Restored to WT levels).

    “ATH434, given after dysfunction was established, resulted in a reversal of slowed colonic propulsion and gut transit deficits in A53T mice to WT levels.”

    AnimalsA53T alpha-synuclein transgenic mice with established dysfunctioncolon30 mg/kg/day4 months

    ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease

    Journal of Parkinson's disease

Who is developing ATH434?

1 company: Alterity Therapeutics.

Companies
  • Alterity TherapeuticsPhase 2multiple system atrophy

Trial sponsors

Latest